GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Short-Term Debt

Aprinoia Therapeutics (Aprinoia Therapeutics) Short-Term Debt : $15.48 Mil (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Short-Term Debt?

Aprinoia Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2023 was $15.48 Mil.

Aprinoia Therapeutics's quarterly Short-Term Debt increased from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($2.54 Mil) and increased from Dec. 2022 ($2.54 Mil) to Jun. 2023 ($15.48 Mil).

Aprinoia Therapeutics's annual Short-Term Debt increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.79 Mil) and increased from Dec. 2021 ($0.79 Mil) to Dec. 2022 ($2.54 Mil).

Aprinoia Therapeutics Short-Term Debt Historical Data

The historical data trend for Aprinoia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Short-Term Debt Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Short-Term Debt
0.79 2.54

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Short-Term Debt 0.79 - 2.54 15.48

Aprinoia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Aprinoia Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Short-Term Debt
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines